UK Heart Failure With Preserved Ejection Fraction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorManchester University NHS Foundation Trust
About this trial
Heart failure occurs when the heart is no longer able to pump blood around the body properly. It can cause breathlessness, swollen feet and ankles, and tiredness. In about half of patients with heart failure, one measure of the heart's pumping function, called the 'ejection fraction', is normal. This type of heart failure is called heart failure with preserved ejection fraction, or HFpEF.
HFpEF remains poorly understood. It is not clear why some people develop HFpEF, or what determines the severity of the condition. Treatment options may be limited.
UK HFpEF is a study that aims to gain a better understanding of why people develop HFpEF, develop better tests to diagnosis it, identify and test new treatments, and follow the health of the people taking part over many years.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Written informed consent
Diagnosis of HFpEF by a cardiologist with HF expertise, or a primary care physician with HF expertise, or a heart failure nurse
Natriuretic peptide levels measured
Disqualifiers
LV EF < 40% (at screening or any previous measurement)
Known infiltrative cardiomyopathy (e.g., amyloid, sarcoid, lymphoma, endomyocardial fibrosis)
Known active myocarditis, constrictive pericarditis, or cardiac tamponade
Known genetic hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy
Trial population
All individuals will be considered for inclusion in this study regardless of age, disability, gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion and belief, sex, and sexual orientation, except where the study inclusion and exclusion criteria explicitly state otherwise.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Identification of distinct subgroups of HFpEF
Identify distinct subgroups of HFpEF based on disease mechanisms, clinical factors and outcomes
Time frame
10 years2
Improve understanding of the causes of HFpEF
Improve the understanding of the cause of HFpEF to provide the basis for developing and evaluating new therapies and diagnostics
Time frame
10 years3
Improve risk stratification of HFpEF
Identify and improve risk stratification models for HFpEF patients
Time frame
10 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Manchester University NHS Foundation Trust
Lead sponsor
Pumping Marvellous Foundation
Collaborator
British Society for Heart Failure
Collaborator
National Institute for Health Research, United Kingdom
Collaborator
British Heart Foundation Data Science Centre
Collaborator
Source ClinicalTrials.gov